CRP and hyperlipidemia: A comparison of the cardiovascular benefits and risks of diabetes from statin therapy based on the results of the JUPITER trial49 previously concluded that the cardiovascular benefits of rosuvastatin greatly outweighed the risks of new-onset diabetes, despite this trial being conducted in a primary prevention setting among apparently healthy people (without hyperlipidaemia but with increased concentration of CRP on a high-sensitivity CRP test).